Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant prostate cancer (mCRPC) according to new results from the AFFIRM study published in Lancet Oncology.

Bone is the most common site of spread in prostate cancer, accounting for about 90% of metastases, resulting in some of the most painful and functionally compromising complications of the disease.

Professor Johann De Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research London, and Head of the Drug Development Unit at The Royal Marsden NHS Foundation Trust, comments: “These quality of life data endorse the fact that enzalutamide is a major advance in the treatment of prostate cancer.”

Continue Reading

READ FULL ARTICLE Curated publisher From Medical News Today